A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
Public ClinicalTrials.gov record NCT06812494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Controlled, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies given intravenously in adult participants without HIV. The hypothesis of the study is that the combination of VRC07-523LS and PGT121.414.LS and PGDM1400LS antibodies when administered via the intravenous (IV) route will be safe and tolerable in adult participants without HIV. The study aims to enroll 200 participants across multiple sites with an estimated total duration of participation of eighteen (18) months.
Study identification
- NCT ID
- NCT06812494
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- VRC07-523LS 400mg Biological
- PGT121.414.LS 400mg Biological
- PGDM1400LS 400mg Biological
- VRC07-523LS 3200mg Biological
- PGT121.414.LS 1600mg Biological
- PGDM1400LS 1600mg Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2025
- Primary completion
- Jan 14, 2027
- Completion
- Sep 14, 2027
- Last update posted
- Aug 20, 2026
2025 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRA (Site #31788) | Birmingham | Alabama | 35222 | — |
| Bridge HIV, San Francisco Department of Public Health | San Francisco | California | 94102 | — |
| The Hope Clinic of the Emory Vaccine Research Center; Emory University | Decatur | Georgia | 30030 | — |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) | Boston | Massachusetts | 02115-6110 | — |
| Fenway Health | Boston | Massachusetts | 02215-4302 | — |
| BIDMC VCRS (Site ID# 32077) | Boston | Massachusetts | 02215 | — |
| Columbia P&S CRS | New York | New York | 10032 | — |
| University of Rochester Vaccines to Prevent HIV Infection CRS (Site ID 31467) | Rochester | New York | 14642 | — |
| Chapel Hill CRS (Site #3201) | Chapel Hill | North Carolina | 27599 | — |
| Penn Prevention CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS (Site 1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Vaccine (VV) CRS | Nashville | Tennessee | 37232 | — |
| Seattle Vaccine and Prevention CRS (Site ID# 30331) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06812494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06812494 live on ClinicalTrials.gov.